Clinical Cancer Investigation Journal

CASE REPORT
Year
: 2015  |  Volume : 4  |  Issue : 3  |  Page : 438--440

Fluoride-18 fluorodeoxyglucose positron emission tomography-computed tomography in staging and response evaluation of rare case of non-Hodgkin's lymphoma involving adrenals, liver and bone


Koramadai Karuppusamy Kamaleshwaran1, Sudhakar Natarajan2, Anjali Maliakkal1, Vyshak Mohanan1, Ajit Sugunan Shinto1,  
1 Department of Nuclear Medicine, PET/CT and Radionuclide Therapy, Coimbatore, Tamil Nadu, India
2 Department of Medical Oncology, Kovai Medical Center and Hospital Limited, Coimbatore, Tamil Nadu, India

Correspondence Address:
Koramadai Karuppusamy Kamaleshwaran
Department of Nuclear Medicine, PET/CT and Radionuclide Therapy, Comprehensive Cancer Care Center, Kovai Medical Center and Hospital Limited, Coimbatore - 641 014, Tamil Nadu
India

Abstract

Fluoride-18 fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) is increasingly applied in staging and treatment response assessment of lymphomas. Multiple isolated cases with extranodal involvement of non-Hodgkins lymphoma (NHL), detected on FDG PET-CT, have been previously reported. Here, we report a rare case of extranodal NHL involving multiple sites namely bilateral adrenals, liver and tibia in addition to supraclavicular, iliac and inguinal lymph nodes on FDG PET-CT and treatment response was assessed in follow-up FDG PET-CT.



How to cite this article:
Kamaleshwaran KK, Natarajan S, Maliakkal A, Mohanan V, Shinto AS. Fluoride-18 fluorodeoxyglucose positron emission tomography-computed tomography in staging and response evaluation of rare case of non-Hodgkin's lymphoma involving adrenals, liver and bone.Clin Cancer Investig J 2015;4:438-440


How to cite this URL:
Kamaleshwaran KK, Natarajan S, Maliakkal A, Mohanan V, Shinto AS. Fluoride-18 fluorodeoxyglucose positron emission tomography-computed tomography in staging and response evaluation of rare case of non-Hodgkin's lymphoma involving adrenals, liver and bone. Clin Cancer Investig J [serial online] 2015 [cited 2019 Nov 22 ];4:438-440
Available from: http://www.ccij-online.org/text.asp?2015/4/3/438/151952


Full Text

 INTRODUCTION



Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkins lymphoma (NHL) constituting 33% of all cases. The patient can present either with a primary disease of lymph nodes or that of extranodal sites. More than half of the patients have some site of extranodal involvement at the time of initial diagnosis. Any organ can be involved, with the most common sites being the gastrointestinal tract and bone marrow, each being involved in 15-20% of the patients. [1] Adrenals, liver, and bone involvement is quite uncommon in DLBCL. [2] Uncovering such rare sites in one single patient highlights the role of the whole body fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) in staging of lymphomas.

 CASE REPORT



A 20-year-old male presented with swelling in the right inguinal region. Examination revealed right inguinal lymph nodal mass which on biopsy confirmed to be DLBCL. He was referred for a baseline whole body FDG PET-CT. Maximum intensity projection images [Figure 1] revealed multiple foci of increased tracer uptake in bilateral adrenal lesions with liver involvement, right tibial lesion, left supraclavicular, iliac and inguinal lymph nodes. He received four cycles of intravenous bolus chemotherapy regimen, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone. Posttherapy FDG PET-CT revealed no abnormal focus of FDG uptake in the entire body except in left tibia, suggestive of complete metabolic and morphological response to treatment in lymph nodes, adrenal, liver lesions and near complete response in tibial lesion [Figure 2].{Figure 1}{Figure 2}

 DISCUSSION



Non-Hodgkins lymphoma can involve various extranodal sites such as the gastrointestinal tract, bone, brain, testis, ovary, lung, nasopharynx, soft tissue, thyroid, kidney, liver, breast, skin, etc. [1],[3] Non-Hodgkin's lymphoma can involve adrenal in almost 25% of cases, [4] either with nodal involvement or as primary adrenal lymphoma. Clinically, the patients may present with features of Addison disease. Bilateral involvement can be seen in up to 50% of cases. [5]

Secondary involvement of the liver in lymphoma is much more common than primary liver lymphoma, which represents only 0.4% of cases of extranodal lymphoma. [6] Non-Hodgkin's lymphoma is more likely to have hepatic involvement than Hodgkin's lymphoma. Diffuse subtypes are more likely to infiltrate the liver compared to nodular histologies. Secondary hepatic lymphoma is relatively common and often subclinical. [7] Secondary hepatic lymphoma has a wider range of appearances, it may appear as multiple or diffusely infiltrating lesions, but is unlikely to appear as a solitary lesion. [8] Associated increased uptake at portal and retroperitoneal nodes are common findings in secondary lymphomatous involvement of the liver.

Primary involvement of bone is classified as stage I disease; involvement in a disseminated lymphoma is grouped as stage IV. Most are NHL type. DLBCL is the most common type and primary Hodgkin lymphoma of the bone is very rare. [9] Presentation can be of the following patterns: Permeative lytic destruction, blastic sclerotic changes, near normal appearance on CT with the destructive pattern being the most common type. Diffuse or focal skeletal uptake on FDG PET-CT may also represent marrow involvement especially when no definite radiographic changes are noted. [10]

Therefore, whole body imaging with a sensitive modality such as FDG PET-CT is mandatory to assess the extent of disease by detecting unexpected extranodal sites of disease or exclusion of disease in the presence of nonspecific extranodal CT findings. [11] In patients with known disease, other goals can be accomplished, which are evaluation of response to therapy, identification of new or recurrent disease, and monitoring the complications of therapy. In the present study, simultaneous involvement of the bilateral adrenals, liver and the left tibia is detected by FDG PET-CT. It is well known that the final diagnosis of lymphoma is based on the pathological diagnosis. However, for ethical reasons, pathological diagnosis may not be possible for all lesions and abnormalities found. Thus, FDG PET-CT is useful for the detection of unusual extranodal involvement. [12]

 CONCLUSION



Fluorodeoxyglucose positron emission tomography-computed tomography has become an invaluable investigation in staging and response assessment of lymphoma. In conclusion, the present case highlights the utility of FDG PET-CT in detection of extranodal NHL at unsuspected sites that may have an important bearing on the management and prognosis.

References

1Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics 2010;30:269-91.
2Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin′s disease. Radiol Clin North Am 2007;45:697-709, vii.
3López-Guillermo A, Colomo L, Jiménez M, Bosch F, Villamor N, Arenillas L, et al. Diffuse large B-cell lymphoma: Clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-804.
4Kumar R, Xiu Y, Mavi A, El-Haddad G, Zhuang H, Alavi A. FDG-PET imaging in primary bilateral adrenal lymphoma: A case report and review of the literature. Clin Nucl Med 2005;30:222-30.
5Kubo M, Koga M, Fujii T, Kaneko T, Yamashita K, Kokubu T. Bilateral adrenal lymphoma with neoplastic angioendotheliosis. Intern Med 1997;36:47-52.
6Salmon JS, Thompson MA, Arildsen RC, Greer JP. Non-Hodgkin′s lymphoma involving the liver: Clinical and therapeutic considerations. Clin Lymphoma Myeloma 2006;6:273-80.
7Bagley CM Jr, Thomas LB, Johnson RE, Chretien PB, DeVita VT Jr. Diagnosis of liver involvement by lymphoma: Results in 96 consecutive peritoneoscopies. Cancer 1973;31:840-7.
8Gazelle GS, Lee MJ, Hahn PF, Goldberg MA, Rafaat N, Mueller PR. US, CT, and MRI of primary and secondary liver lymphoma. J Comput Assist Tomogr 1994;18:412-5.
9Harisankar CN, John J, Lekshmi TP, Warrier A. 18 Fluoride-fluorodeoxyglucose positron emission tomography in initial staging and response assessment of primary non-Hodgkin lymphoma of the tibia. Indian J Nucl Med 2014;29:260-1.
10Park YH, Kim S, Choi SJ, Ryoo BY, Yang SH, Cheon GJ, et al. Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone. Ann Oncol 2005;16:1401-2.
11Puranik AD, Agrawal A, Purandare NC, Shah S, Rangarajan V. Four rare extranodal sites seen on FDG PET/CT in a single patient of disseminated lymphoma. Indian J Med Paediatr Oncol 2013;34:101-3.
12D′souza MM, Jaimini A, Bansal A, Tripathi M, Sharma R, Mondal A, et al. FDG-PET/CT in lymphoma. Indian J Radiol Imaging 2013;23:354-65.